

Hepatitis C in Primary Care & Drug and Alcohol Settings

Treating hepatitis C in people who inject drugs

People who inject drugs (PWID) represent approximately 90% of newly acquired hepatitis C (HCV) infection. Clinicians working with PWID play an important role in reducing HCV-related morbidity and mortality through early diagnosis and treatment.

With the advent of new well-tolerated, short-course direct acting antiviral (DAA) HCV regimens with cure rates >95%, there is a chance to vastly improve the health outcomes of people living with HCV.

This course will strengthen the capacity of clinical staff to test for, treat and manage HCV in their setting. Through online learning and a face-face workshop, delivered by local experts, participants will gain the skills to confidently prescribe the new DAAs.

At the conclusion of this program, participants will be able to:

- Describe the risk factors for HCV infection, enabling effective practice screening processes and prevention education
- Demonstrate competence interpreting clinical information to effectively diagnose HCV
- Demonstrate competence in liver disease assessment
- Demonstrate understanding of DAA therapy for the treatment of HCV and competence in selecting and prescribing appropriate therapy
- Monitor patients on treatment and post-treatment appropriately

Date:

Monday, 20 November 2017

Time:

9:00am - 5:00pm (registration from 8:30am)

Venue:

To be confirmed

Address:

To be confirmed, Mississauga, Ontario

Cost:

The course is free of charge; refreshments, morning and afternoon tea and lunch will be provided.

Speakers:

To be confirmed

Registration link:

<https://ashm.eventsair.com/inhsu/hcvworkshopmississauga>

Register before:

Monday, 13 November 2017

For further details contact

info@inhsu.org

Travel scholarships are available.

For more information contact info@inhsu.org

Certification:

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada, and accredited by the Canadian Association for the Study of the Liver. Participants can claim up to a maximum of 6.0 study credits.

This Symposium is convened by the International Network on Hepatitis in Substance Users



This Course has been funded with unrestricted educational grants by Gilead Sciences Canada, Inc. and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.